ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.
한글목차
올리고뉴클레오티드 치료제 시장 규모는 향후 수년간 빠르게 성장할 것으로 예상되며, 2029년에는 연평균 12.3%의 성장률로 98억 2,000만 달러에 달할 것으로 예상됩니다. 예측 기간의 성장은 R&D 투자, 세계 시장 침투, 치료 영역 확대, 질병 변형 전략, 규제 적응에 기인하는 것으로 추정됩니다. 예측 기간의 주요 동향으로는 맞춤 치료, 전달 시스템의 발전, RNA 간섭(RNAI)의 발전, 안티센스 올리고뉴클레오티드의 혁신, 유전자 편집 기술의 통합 등이 있습니다.
세계 암 환자 증가는 예측 기간 중 올리고뉴클레오티드 치료제 시장의 성장에 기여할 것으로 예상됩니다. 예를 들어 미국암협회는 2022년 1월 현재 미국에서 약 190만 명이 새로 암 진단을 받고 60만 9,360명이 암으로 사망하며, 하루 평균 약 1,670명이 사망할 것으로 예측했습니다. 폐암, 전립선암, 장암, 여성 유방암 등 전 세계에서 가장 발병률이 높은 암종은 전체 신규 암 환자의 43%를 차지합니다. 이에 따라 전 세계 암 발병률의 급격한 증가는 향후 수년간 올리고뉴클레오티드 치료제 시장 수요를 견인할 것으로 예상됩니다.
헬스케어 연구개발을 위한 정부 구상은 올리고뉴클레오티드 치료제 시장의 성장을 가속할 것으로 예상됩니다. 이러한 구상에는 특정 문제를 해결하고, 정의된 목표를 달성하고, 사회에 긍정적인 변화를 가져오기 위해 다양한 수준(지방, 지역, 국가, 국제)의 정부 당국이 시행하는 특정 행동, 프로그램, 정책 및 프로젝트가 포함됩니다. 다양한 정부 기관이 올리고뉴클레오티드 요법을 포함한 다양한 측면을 지원하기 위해 다양한 정부 기관이 헬스케어 구상을 시작하고 있으며, 2022년 영국 정부는 보건사회부(Department of Health and Social Care)로서 헬스케어 연구 및 제조를 강화하기 위해 BEIS와 DHSC가 제공하는 이 자금은 새로운 프라이버시 보호 플랫폼과 임상 연구 서비스를 통해 NHS 주도의 진단 및 치료 건강 연구를 지원하는 것을 목표로 하고 있습니다. 또한 영국내 생명과학 제조 산업의 확장을 지원하기 위해 6,000만 파운드(6,360만 달러)가 배정되었습니다.
목차
제1장 개요
제2장 시장의 특징
제3장 시장 동향과 전략
제4장 시장 - 거시경제 시나리오 금리, 인플레이션, 지정학, Covid, 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오
제5장 세계의 성장 분석과 전략 분석 프레임워크
세계 올리고뉴클레오티드 요법 PESTEL 분석(정치, 사회, 기술, 환경, 법적 요인, 촉진요인, 억제요인)
최종 용도 산업의 분석
세계의 올리고뉴클레오티드 요법 시장 : 성장률 분석
세계의 올리고뉴클레오티드 요법 시장 실적 : 규모와 성장, 2019-2024
세계의 올리고뉴클레오티드 요법 시장 예측 : 규모와 성장, 2024-2029, 2034F
세계 올리고뉴클레오티드 요법 TAM(Total Addressable Market)
제6장 시장 세분화
세계의 올리고뉴클레오티드 요법 시장 : 유형별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
안티센스 올리고뉴클레오티드
압타머
기타 유형
세계의 올리고뉴클레오티드 요법 시장 : 용도별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
감염증
종양학
신경변성질환
심혈관질환
신장질환
기타 최종사용자
세계의 올리고뉴클레오티드 요법 시장 : 최종사용자별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
병원
조사기관
세계의 올리고뉴클레오티드 요법 시장 안티센스 올리고뉴클레오티드의 서브 세분화, 유형별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
RNA 표적 안티센스 올리고뉴클레오티드
DNA 표적 안티센스 올리고뉴클레오티드
화학적으로 수식된 안티센스 올리고뉴클레오티드
세계의 올리고뉴클레오티드 요법 시장, 압타머의 서브 세분화, 유형별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
DNA 압타머
RNA 압타머
소분자 압타머
세계의 올리고뉴클레오티드 요법 시장, 기타 유형의 서브 세분화, 유형별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
siRNA(저분자 간섭 RNA)
miRNA(마이크로 RNA)
DNA자임과 리보자임
유전자 편집용 합성 올리고뉴클레오티드
제7장 지역별·국가별 분석
세계의 올리고뉴클레오티드 요법 시장 : 지역별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
세계의 올리고뉴클레오티드 요법 시장 : 국가별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
제8장 아시아태평양 시장
제9장 중국 시장
제10장 인도 시장
제11장 일본 시장
제12장 호주 시장
제13장 인도네시아 시장
제14장 한국 시장
제15장 서유럽 시장
제16장 영국 시장
제17장 독일 시장
제18장 프랑스 시장
제19장 이탈리아 시장
제20장 스페인 시장
제21장 동유럽 시장
제22장 러시아 시장
제23장 북미 시장
제24장 미국 시장
제25장 캐나다 시장
제26장 남미 시장
제27장 브라질 시장
제28장 중동 시장
제29장 아프리카 시장
제30장 경쟁 구도와 기업 개요
올리고뉴클레오티드 요법 시장 : 경쟁 구도
올리고뉴클레오티드 요법 시장 : 기업 개요
Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
GlaxoSmithKline plc Overview, Products and Services, Strategy and Financial Analysis
Gilead Sciences Inc. Overview, Products and Services, Strategy and Financial Analysis
BioNTech SE Overview, Products and Services, Strategy and Financial Analysis
제31장 기타 대기업과 혁신적 기업
Moderna Inc.
Biogen Inc.
Jazz Pharmaceuticals plc
QIAGEN Company
Alnylam Pharmaceuticals Inc.
Sarepta Therapeutics Inc.
Ionis Pharmaceuticals Inc.
Akcea Therapeutics Inc.
Arrowhead Pharmaceuticals Inc.
Dicerna Pharmaceuticals Inc.
SomaGenics Inc.
Wave Life Sciences Ltd.
Exicure Inc.
Avidity Biosciences Inc.
Miragen Therapeutics Inc.
제32장 세계의 시장 경쟁 벤치마킹과 대시보드
제33장 주요 합병과 인수
제34장 최근 시장 동향
제35장 시장의 잠재력이 높은 국가, 부문, 전략
올리고뉴클레오티드 요법 시장 2029 : 새로운 기회를 제공하는 국가
올리고뉴클레오티드 요법 시장 2029 : 새로운 기회를 제공하는 부문
올리고뉴클레오티드 요법 시장 2029 : 성장 전략
시장 동향에 기반한 전략
경쟁사 전략
제36장 부록
KSA
영문 목차
영문목차
Oligonucleotide therapy is a comprehensive term encompassing advanced molecular-targeting agents that utilize chemically synthesized oligonucleotides featuring single-stranded DNA (DNA) or RNA (RNA) backbones with inherent selectivity. Oligonucleotides are designed to form base pairs with DNA or RNA strands for various applications, with their most prevalent use being in PCR primers (polymerase chain reaction).
The primary categories of oligonucleotide therapy include antisense oligonucleotides, aptamers, and others. Antisense oligonucleotides (AS ONs) are artificial DNA oligomers designed to hybridize with a specific target RNA sequence. They have proven effective in limiting gene expression, modifying precursor messenger RNA splicing, and deactivating microRNAs. This therapeutic approach finds applications in infectious diseases, oncology, neurodegenerative disorders, cardiovascular diseases, kidney diseases, among others, and is applied in healthcare facilities and research institutes.
The oligonucleotide therapy market research report is one of a series of new reports from The Business Research Company that provides oligonucleotide therapy market statistics, including oligonucleotide industry global market size, regional shares, competitors with an oligonucleotide market share, detailed oligonucleotide therapy market segments, market trends, and opportunities, and any further data you may need to thrive in the oligonucleotide industry. This oligonucleotide therapy market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.
The oligonucleotide therapy market size has grown rapidly in recent years. It will grow from $5.55 billion in 2024 to $6.18 billion in 2025 at a compound annual growth rate (CAGR) of 11.4%. The growth in the historic period can be attributed to growth in investment in research and development, market entry of early therapies, rise of gene editing techniques, early therapeutic discoveries, rnai and antisense oligonucleotide introduction.
The oligonucleotide therapy market size is expected to see rapid growth in the next few years. It will grow to $9.82 billion in 2029 at a compound annual growth rate (CAGR) of 12.3%. The growth in the forecast period can be attributed to research and development investments, global market penetration, therapeutic area expansion, disease modification strategies, regulatory adaptations. Major trends in the forecast period include customized therapies, advancements in delivery systems, rna interference (RNAI) advancements, antisense oligonucleotide innovation, gene editing techniques integration.
The increase in cancer cases globally is expected to contribute to the oligonucleotide therapy market's growth during the forecast period. For example, as of January 2022, the American Cancer Society projected approximately 1.9 million new cancer diagnoses and 609,360 cancer-related deaths in the US, averaging around 1,670 fatalities daily. The most prevalent cancer types globally-lung, prostate, bowel, and female breast cancer-constitute 43% of all new cancer cases. Consequently, the surge in global cancer incidence rates is poised to drive the oligonucleotide therapy market's demand in the coming years.
Government initiatives aimed at research and development in healthcare are anticipated to boost the oligonucleotide therapy market's growth. These initiatives involve specific actions, programs, policies, or projects undertaken by government authorities at various levels (local, regional, national, or international) to address specific issues, achieve defined goals, or instigate positive changes in society. Various government bodies are launching healthcare initiatives to support different aspects, including oligonucleotide therapy. In 2022, the UK government, as per the Department of Health and Social Care, committed £260 million (US $270.65 million) in funding to enhance healthcare research and manufacturing. This funding, provided by BEIS and DHSC, aimed to support NHS-led health research in diagnostics and treatment through new privacy-preserving platforms and clinical research services. Additionally, £60 million (US $63.60 million) was allocated to assist in expanding life sciences manufacturing in the UK.
Developers and providers in the oligonucleotide therapy market are investing in research and development to redesign therapy approaches. Innovative oligonucleotides enable precision medicine, selectively targeting genes with minimal side effects, and addressing patient-specific sequences causing rare diseases. In April 2023, the FDA approved Qalsody, an antisense oligonucleotide (ASO), for treating ALS associated with the SOD1 gene mutation. Qalsody targets SOD1 mRNA to reduce protein synthesis.
Major companies in the oligonucleotide therapy market are introducing pediatric-focused therapies to drive market revenues. Elevidys, the first FDA-approved gene therapy for Duchenne muscular dystrophy (DMD) in pediatric patients aged 4 through 5, showcases advancements in gene-based treatments for genetic diseases, although not specifically an oligonucleotide therapy.
In September 2022, Vanda Pharmaceuticals, a US-based biopharmaceutical company, and OliPass, a South Korea-based biotechnology company, announced a strategic partnership to develop antisense oligonucleotide (ASO) therapeutics. This collaboration aims to jointly develop a series of ASO molecules based on OliPass' proprietary modified peptide nucleic acids, leveraging the strengths of both companies to advance ASO-based precision medicine therapeutics.
North America was the largest region in the oligonucleotide therapy market in 2024. The regions covered in the oligonucleotide therapy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
The countries covered in the oligonucleotide therapy market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain
The oligonucleotide therapy market consists of sales of ASOs, siRNAs, miRNAs, and DNAzymes. Values in this market are factory gate values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Oligonucleotide Therapy Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on oligonucleotide therapy market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase
Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market shares.
Benchmark performance against key competitors.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.
Where is the largest and fastest growing market for oligonucleotide therapy ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The oligonucleotide therapy market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
The market characteristics section of the report defines and explains the market.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include:
The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.
Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
Markets Covered:1) By Type: Antisense Oligonucleotide; Aptamer; Other Types
2) By Application: Infectious Diseases; Oncology; Neurodegenerative Disorders; Cardiovascular Diseases; Kidney Diseases; Other End-User
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery format: PDF, Word and Excel Data Dashboard.
Table of Contents
1. Executive Summary
2. Oligonucleotide Therapy Market Characteristics
3. Oligonucleotide Therapy Market Trends And Strategies
4. Oligonucleotide Therapy Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market
5. Global Oligonucleotide Therapy Growth Analysis And Strategic Analysis Framework
5.1. Global Oligonucleotide Therapy PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
5.2. Analysis Of End Use Industries
5.3. Global Oligonucleotide Therapy Market Growth Rate Analysis
5.4. Global Oligonucleotide Therapy Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
5.5. Global Oligonucleotide Therapy Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
5.6. Global Oligonucleotide Therapy Total Addressable Market (TAM)
6. Oligonucleotide Therapy Market Segmentation
6.1. Global Oligonucleotide Therapy Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Antisense Oligonucleotide
Aptamer
Other Types
6.2. Global Oligonucleotide Therapy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Infectious Diseases
Oncology
Neurodegenerative Disorders
Cardiovascular Diseases
Kidney Diseases
Other End-User
6.3. Global Oligonucleotide Therapy Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Hospitals
Research Institutes
6.4. Global Oligonucleotide Therapy Market, Sub-Segmentation Of Antisense Oligonucleotide, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
RNA-Targeted Antisense Oligonucleotides
DNA-Targeted Antisense Oligonucleotides
Chemically Modified Antisense Oligonucleotides
6.5. Global Oligonucleotide Therapy Market, Sub-Segmentation Of Aptamer, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
DNA Aptamers
RNA Aptamers
Small Molecule Aptamers
6.6. Global Oligonucleotide Therapy Market, Sub-Segmentation Of Other Types, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
siRNA (Small Interfering RNA)
miRNA (Micro RNA)
DNAzyme And Ribozymes
Synthetic Oligonucleotides For Gene Editing
7. Oligonucleotide Therapy Market Regional And Country Analysis
7.1. Global Oligonucleotide Therapy Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
7.2. Global Oligonucleotide Therapy Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
